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Abstract: 
Background and Purpose: Prophylactic anticonvulsants are routinely prescribed in the acute 
setting for ICH patients, but some studies have reported an association with worse outcomes. We 
sought to characterize the prevalence and predictors of prophylactic anticonvulsant 
administration after ICH as well as guideline adherence. We also sought to determine if 
prophylactic anticonvulsants were independently associated with poor outcome. 
Methods: We performed a retrospective study of primary ICH in our two academic centers. We 
used a propensity matching approach to make treated and non-treated groups comparable. We 
conducted multiple logistic regression analysis to identify independent predictors of prophylactic 
anticonvulsant initiation and its association with poor outcome as measured by modified Rankin 
score.  
Results: We identified 610 patients with primary ICH, of whom 98 were started on prophylactic 
anticonvulsants. Levetiracetam (97%) was most commonly prescribed. Age (OR: 0.97, 95% CI: 
0.95-0.99, p < .001), lobar location (OR: 2.94, 95% CI: 1.76-4.91, p < .001), higher initial 
NIHSS score (OR: 2.31, 95% CI: 1.40-3.79, p = .001), craniotomy (OR: 3.06, 95% CI: 1.51-
6.20, p = .002) and prior ICH (OR: 2.36, 95% CI: 1.10-5.07, p = .028) were independently 
associated with prophylactic anticonvulsant initiation. Prophylactic anticonvulsant use was not 
associated with worse functional outcome (mRS 4-6) at hospital discharge or with increased 
case-fatality. There was no difference in prescribing patterns after 2010 guideline publication. 
Discussion: Levetiracetam was routinely prescribed following ICH and was not associated with 
worse outcomes. Future investigations should examine the effect of prophylactic levetiracetam 
on cost and neuropsychological outcomes as well as the role of continuous EEG in identifying 
subclinical seizures. 
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Introduction: 
Intracerebral hemorrhage (ICH) has high morbidity and mortality1 and treatment remains largely 
supportive. Seizures are a common complication in the acute setting2 and prophylactic treatment 
with anticonvulsants is common,3 though the guidelines have recommended that patients without 
seizures should not receive prophylactic anticonvulsants.4, 5 Whether prophylactic 
anticonvulsants are associated with poor outcome in ICH remains unclear.3, 6-9 We therefore 
sought to identify factors associated with prophylactic anticonvulsant initiation and to determine 
whether prophylactic anticonvulsants were independently associated with poor clinical outcome. 
We also sought to evaluate whether prophylactic anticonvulsant prescribing patterns changed 
after guideline publication in 2010. 
 
Methods:  
This study was approved by the Indiana University Institutional Review Board, the Indiana 
Network for Patient Care (INPC) board of directors, and Wishard Memorial Hospital. 
Cohort assembly 
We evaluated all patients ≥18 years old with primary ICH presenting to two academic centers via 
a query of the INPC database (http://www.ihie.org). The INPC is a health information exchange 
serving multiple hospital systems in Central Indiana.10 For inclusion in the study the index ICH 
had to occur between January 1, 2009 and December 31, 2011; we additionally queried the 
database until February 29, 2012 to identify patients with an index ICH during the study period 
but who were subsequently discharged in the following two months. We used discharge ICD-9 
codes of 431 and 432.9 to identify potential cases; these codes have >85% sensitivity for the 
identification of patients with ICH.11 A vascular neurologist (J.M.) reviewed the medical record 
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and imaging scans of all potential cases to ensure proper case characterization. Patients with 
evidence of traumatic ICH or an aneurysm, encephalitis, or brain tumor as a cause of the 
hemorrhage were excluded. Patients with hemorrhagic transformation of an ischemic infarct or 
hemorrhage due to venous sinus thrombosis, carotid endarterectomy, or thrombolytic 
administration for ischemic stroke were also excluded.  
 
Clinical data abstraction 
Under the close supervision of a vascular neurologist, data abstractors ascertained via 
standardized chart review demographic data, vascular risk factors, and processes of care. All 
available referring hospital and transfer data were reviewed. If a formal NIH stroke scale 
(NIHSS) score was not reported at presentation we used a validated method for estimation.12 The 
neurologist reviewed the initial imaging scan from the academic center for each patient as well 
as all available imaging scans from the referring hospital. Hematoma volume was calculated with 
the ABC/2 method.13 
 
Clinical outcome measures included modified Rankin score (mRS) at discharge. Date, time, and 
cause of death were recorded for patients who died during the hospitalization. Discharge 
disposition was also recorded. We determined vital status via present-day chart review and 
obituary query. We then performed a National Death Index (http://www.cdc.gov/nchs/ndi.htm) 
query for the vital status of all patients for whom we still could not account. All clinical data 
were recorded in REDCap.14 
 
Prophylactic anticonvulsant abstraction 
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For the prophylactic anticonvulsant analysis, we excluded patients with a history of seizure, 
those with witnessed or suspected seizures, and those with baseline mRS of 4 or 5. We identified 
time and location for first prophylactic anticonvulsant use and abstracted all medications and 
doses for the duration of the hospitalization. For each day we calculated the daily dose of the 
prophylactic anticonvulsants using the World Health Organization defined daily dose (DDD) 
classification for levetiracetam (1500mg), phenytoin (300mg), and fosphenytoin (450mg), 
(http://www.whocc.no/ddd/definition_and_general_considera/), as well as the number of dose 
days, the average daily dose, and the cumulative dose for each patient. For example, if a patient 
received levetiracetam 500mg BID for a total of 3 days the mean daily dose would be 0.67 
(1000/1500) and the cumulative dose would be 2 (0.67*3). We also reviewed all available 
documentation to determine whether the patient was discharged on the prophylactic 
anticonvulsant. We further reviewed the entirety of the available medical record and abstracted 
the last known prophylactic anticonvulsant administration.  
 
Statistical Methods 
Our two dichotomous primary outcomes were whether a patient had a prophylactic 
anticonvulsant administered and whether a patient had worse functional outcome at hospital 
discharge as measured by mRS of 4-6. We assembled the prophylactic anticonvulsant cohort for 
the first primary outcome and the functional outcome cohort for the second primary outcome as 
described below. To analyze the functional outcome data, we assessed how comparable the 
treatment and corresponding matched control groups were at baseline. Chi-square, Fisher’s 
exact, Student’s t, or Wilcoxon rank sum tests were used for this comparison. We considered 
several covariates as listed in Table 1 to identify factors associated with each of the two primary 
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outcomes and used univariate and multiple logistic regression analyses. These variables included 
general patient characteristics, variables significant in previous studies, and variables which 
treating physicians may have considered as predisposing patients to higher seizure risk. We 
assessed the association at univariate level and the covariates found to be significant at a p-value 
of <0.20 were included in a stepwise multiple logistic regression model. Statistical analyses were 
performed with SAS version 9.4 (SAS institute, Cary NC).  
 
Prophylactic anticonvulsant analysis cohort assembly (total n=506) 
Of the 610 patients in the overall cohort, 41 (6.7%) were excluded because of a previous history 
of seizures and 45 (7.4%) had a witnessed or suspected seizure associated with the index ICH 
prior to anticonvulsant initiation. An additional 18 patients were excluded from this analysis 
because the baseline mRS was 4 (n=16) or 5 (n=2). The final cohort therefore included 506 
patients, with 98 who were administered a prophylactic anticonvulsant and 408 who were not 
administered a prophylactic anticonvulsant. 
 
Functional outcome analyses cohort assembly (total n=186) 
We then constructed a control group of patients (a group of patients not treated with prophylactic 
anticonvulsants) who would be as comparable to the treated group of patients as possible. We 
used the propensity score based matching approach and matched each treated patient to a control 
patient if the difference in propensity score was within a pre-defined standard propensity score 
caliper. Using calipers of width equal to 0.2 of the pooled standard deviation of the logit of the 
propensity score removes about 99% of the bias due to the measured confounders.15 For each 
treated patient we selected a control patient if the absolute difference of the propensity score on 
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the logit scale was within 0.2 of the pooled standard deviation of the logit of the propensity 
score. The matching was done without replacement. We identified 93 control patients as a match 
to 93 treated patients. We could not identify a suitable match for 5 of the treated patients. 
 
Results: 
We identified 506 patients with primary ICH from 2009 to 2011, of whom 98 (19.4%) were 
given a prophylactic anticonvulsant, and 408 (80.6%) who were not given a prophylactic 
anticonvulsant. Of the 98 given a prophylactic anticonvulsant, 45 (45.9%) presented to a 
referring hospital initially. The mean age was 61.5, 50 (51.0%) were women, and 33 (33.7%) 
were black. Mean ICH volume was 28.5mL and 52 (53.1%) had intraventricular extension. 
Overall 22 (22.5%) patients died in the hospital and 40 (40.8%) died in the first year following 
ICH.  
 
Of the 408 not given a prophylactic anticonvulsant, 272 (66.7%) presented to a referring hospital 
initially. The mean age was 67.2, 184 (45.1%) were women, and 100 (24.5%) were black. Mean 
ICH volume was 18.8mL and 191 (46.8%) had intraventricular extension. Overall 79 (19.4%) 
patients died in the hospital and 153 (37.5%) died in the first year following ICH. 
 
Prophylactic anticonvulsant analysis  
Levetiracetam alone was prescribed in 95 of 98 (97%) cases; one patient was prescribed both 
levetiracetam and phenytoin, one was prescribed phenytoin alone, and one was prescribed 
phenytoin and a single dose of fosphenytoin. Initiation of prophylactic anticonvulsants occurred 
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in the ICU (61, 62.2%), academic center ED (26, 26.5%), on the hospital floor (5, 5.1%), in the 
operating room (4, 4.1%), and at the outside hospital (2, 2%). 
 
 The univariate analysis assessing association of factors with initiation of prophylactic 
anticonvulsant is shown in Table 1. Younger age, lower baseline mRS, lower GCS, higher 
NIHSS score, greater ICH volume, supratentorial ICH, lobar location, and craniotomy were 
associated with prophylactic anticonvulsant use. The multiple logistic regression analysis is 
shown in Table 2. Younger age, craniotomy, prior ICH, higher NIHSS score, and lobar location 
were independently associated with prophylactic anticonvulsant initiation.  
 
Duration and intensity subanalysis  
For the 98 patients prescribed prophylactic anticonvulsants, the mean and median duration of 
treatment in the hospital was 11.7 days and 6.5 days, respectively. The mean daily dose and 
median daily dose were 0.6125 and 0.6132, respectively. The median cumulative dose was 4.0 
(1.7, 9.0).  
 
Functional outcomes analyses 
After using the propensity score based matching approach, the treated and control groups were 
found to be very similar in demographic characteristics and clinical outcomes as shown in Table 
3. Univariate and multiple logistic regression analyses results for association with worse mRS of 
4-6 are shown in Tables 4 and 5, respectively. Prophylactic anticonvulsant initiation was not 
associated with worse functional outcome of mRS either in unadjusted or adjusted analyses for 
other significant predictors of mRS. Higher NIHSS score, greater ICH volume, intraventricular 
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extension, and worse baseline mRS were independently associated with worse functional 
outcome of mRS at discharge.  
 
Prophylactic anticonvulsants were also not associated with higher inpatient case-fatality or with 
case-fatality at one year in univariate analysis (data not shown). 
 
Prophylactic anticonvulsants at discharge and afterward 
Of the 98 patients started on prophylactic anticonvulsants, 2 (2%) had a subsequent seizure 
during the admission and 74 of the 96 remaining (77.1%) survived to discharge. Of the 42 
(56.8%) patients discharged from the hospital on a prophylactic anticonvulsant, 13 (31%) were 
still on an anticonvulsant at 3 months and 6 (14.3%) were still on an anticonvulsant at 1 year 
following index ICH. 
 
Guideline implementation 
We also dichotomized the study time period into before and after online 2010 guideline 
publication (online July 22, 2010)4 to assess the effect of the guideline on anticonvulsant 
prescribing patterns. Of 284 patients admitted prior to online ICH guideline publication, 55 
(19.4%) were given prophylactic anticonvulsants compared with 43 of 222 (19.4%) after. 
 
Discussion: 
We found that levetiracetam was routinely prescribed in our ICH population and that there was 
no association with worse outcomes at hospital discharge or at one year. From a resource 
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utilization standpoint, prophylactic anticonvulsants were very commonly continued through 
hospital discharge and, in some cases, months or even years afterward. We also found no 
significant change in prescribing habits after a new guideline recommended against prophylaxis 
in 2010. 
 
Several studies in recent years have evaluated the prevalence and predictors of anticonvulsant 
prophylaxis in ICH as well as a potential association with poor outcome. Prevalence of 
prophylaxis has generally ranged from 20-40%.7, 8, 16, 17 In one study investigators evaluated 295 
subjects from the placebo arm of the CHANT trial and found that prophylactic anticonvulsants 
were independently associated with a very poor outcome (mRS of 5 or 6.)3 The most commonly 
prescribed anticonvulsant was phenytoin. Another large study, also predominantly with 
phenytoin, found that prophylactic anticonvulsants were associated with reduced 90-day 
mortality and improved 90-day functional outcome, but these associations disappeared when the 
analysis was restricted to patients surviving beyond five days in an effort to diminish 
confounding by indication.7  
 
More recent studies have evaluated levetiracetam in ICH patients. A prospective study of 98 
patients, of whom 40 received prophylactic anticonvulsants, found that phenytoin was associated 
with poor outcome (mRS 4-6) at 3 months but that levetiracetam was not. This study also 
evaluated duration and intensity of therapy and reported a median duration of about 1 week. 
Most patients receiving levetiracetam were prescribed 500mg BID.6 Other studies comparing 
levetiracetam and phenytoin have found that levetiracetam was associated with improved 
cognitive outcomes at discharge and fewer seizures18 as well as improved long-term outcomes.19 
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A large study using a portion of the ERICH cohort found that prophylactic levetiracetam was not 
independently associated with poor outcome. After adjustment for multiple factors associated 
with poor outcome, prophylactic levetiracetam was not associated with worse functional 
outcome at 3 months.8  
 
Our study confirms these findings and extends them by including a rigorous propensity score 
matching analysis to our outcome models. Levetiracetam is a newer anticonvulsant whose 
precise mechanism of action is unclear. Levetiracetam has fewer side effects and drug 
interactions than phenytoin.20 A recent multicenter study found that levetiracetam use increased 
between 2007 and 2012 with a corresponding decrease in phenytoin use,17 which may reflect 
changes in prescribing behavior based on a study suggesting potential harm from phenytoin.6 
That we did not identify an association with levetiracetam and adverse outcomes is unsurprising 
but reassuring nonetheless. 
 
Strengths of this study include a large, well-characterized cohort, extensive review of referring 
hospital data, and a pre- and post-guideline publication timeframe, as well as the rigorous 
methodology noted above. There are several limitations to this work. This study is retrospective 
in nature with the well-known inherent limitations. Prophylactic anticonvulsant initiation was not 
randomized and was left to the discretion of the treating physician, though we attempted to adjust 
for that using propensity matching. There may also be other factors, such as individual physician 
prescribing habits, that play a role in prophylactic anticonvulsant initiation for which we cannot 
account in this study. Finally, because we did not systematically evaluate patients with 
continuous EEG misclassification bias is possible. 
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In this large retrospective study we found that prophylactic levetiracetam was commonly 
prescribed in our ICH population and that it was not associated with poor functional outcomes at 
hospital discharge or with one-year case-fatality. Future investigations should examine the effect 
of levetiracetam on cost and whether continuous EEG monitoring adds to decision-making about 
anticonvulsants in patients with ICH. Study of the impact of prolonged levetiracetam on quality 
of life and neuropsychological outcomes in ICH patients is also warranted as longer exposure 
could be deleterious. Because there are few specific treatments for ICH, more health services 
research, including guideline adherence research, in ICH is needed as well. Finally, only a 
randomized controlled trial will be able to answer definitively whether ICH patients benefit from 
prophylactic anticonvulsants. 
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Table 1: Univariate logistic regression for prophylactic anticonvulsant (PA) administration 
 
 Not Prescribed PA 
(N = 408) 
Prescribed PA  
(N = 98) 
Unadjusted OR 
(95% CI) for 
predicting PA 
p-value 
N (%) N (%) 
Age - - 0.97 (0.96, 0.99) <.001 
Sex 
Female 
Male 
 
184 (78.6%) 
224 (82.4%) 
 
50 (21.4%) 
48 (17.6%) 
 
1.27 (0.82, 1.97) 
1.00 (– –) 
.292 
Race 
Black 
Non-Black 
 
100 (75.2%) 
308 (82.6%) 
 
33 (24.8%) 
65 (17.4%) 
 
1.56 (0.97, 2.52) 
1.00 (– –) 
.065 
Baseline mRS 
0-1 
2-3 
 
287 (78.2%) 
121 (87.1%) 
 
80 (21.8%) 
18 (12.9%) 
 
1.87 (1.08, 3.26) 
1.00 (– –) 
.026 
GCS - - 0.93 (0.88, 0.98) .007 
Initial NIHSS 
≤ 7 (median) 
     > 7 
 
223 (86.1%) 
185 (74.9%) 
 
36 (13.9%) 
62 (25.1%) 
 
1.00 (– –) 
2.08 (1.32, 3.27) 
.002 
ICH volume (mL) 
Q1 (0-2.3) 
Q2 (2.4-10.1) 
Q3 (10.2-27.0) 
Q4 (27.1-187.5) 
 
117 (90.0%) 
106 (86.2%) 
99 (78.6%) 
84 (67.2%) 
 
13 (10.0%) 
17 (13.8%) 
27 (21.4%) 
41 (32.8%) 
 
1.00 (– –) 
1.44 (0.67, 3.11) 
2.45 (1.20, 5.01) 
4.39 (2.22, 8.71) 
<.001 
Subarachnoid extension 
Yes 
 
40 (75.5%) 
 
13 (24.5%) 
 
1.41 (0.72, 2.75) 
.317 
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 Not Prescribed PA 
(N = 408) 
Prescribed PA  
(N = 98) 
Unadjusted OR 
(95% CI) for 
predicting PA 
p-value 
N (%) N (%) 
No 368 (81.2%) 85 (18.8%) 1.00 (– –) 
Intraventricular extension 
Yes 
No 
 
191 (78.6%) 
217 (82.5%) 
 
52 (21.4%) 
46 (17.5%) 
 
1.28 (0.83, 2.00) 
1.00 (– –) 
.267 
Supratentorial 
Yes 
No 
 
340 (78.7%) 
62 (92.5%) 
 
92 (21.3%) 
5 (7.5%) 
 
3.35 (1.31, 8.58) 
1.00 (– –) 
.012 
Lobar 
Yes 
No 
 
137 (72.9%) 
265 (85.2%) 
 
51 (27.1%) 
46 (14.8%) 
 
2.15 (1.37, 3.36) 
1.00 (– –) 
<.001 
Initial SBP, mmHg 
Q1 (86-155) 
Q2 (156-178) 
Q3 (179-210) 
Q4 (211-282) 
 
104 (83.9%) 
107 (82.9%) 
93 (76.2%) 
95 (79.2%) 
 
20 (16.1%) 
22 (17.1%) 
29 (23.8%) 
25 (20.8%) 
 
1.00 (– –) 
1.07 (0.55, 2.08) 
1.62 (0.86, 3.06) 
1.37 (0.71, 2.62) 
.403 
Initial DBP, mmHg 
Q1 (36-81) 
Q2 (82-98) 
Q3 (99-113) 
Q4 (114-183) 
 
105 (84.7%) 
105 (78.4%) 
96 (81.4%) 
92 (78.0%) 
 
19 (15.3%) 
29 (21.6%) 
22 (18.6%) 
26 (22.0%) 
 
1.00 (– –) 
1.53 (0.81, 2.89) 
1.27 (0.65, 2.48) 
1.56 (0.81, 3.00) 
.514 
Charlson 
0-1 
>1 
 
268 (80.7%) 
140 (80.5%) 
 
64 (19.3%) 
34 (19.5%) 
 
1.00 (– –) 
1.02 (0.64, 1.62) 
.943 
Craniotomy 
Yes 
No 
 
23 (53.5%) 
384 (83.1%) 
 
20 (46.5%) 
78 (16.9%) 
 
4.28 (2.24, 8.17) 
1.00 (– –) 
<.001 
Prior ICH 
Yes 
No 
 
28 (70.0%) 
379 (81.5%) 
 
12 (30.0%) 
86 (18.5%) 
 
1.89 (0.92, 3.86) 
1.00 (– –) 
.081 
Prior ischemic stroke 
Yes 
No 
 
78 (87.6%) 
329 (79.1%) 
 
11 (12.4%) 
87 (20.9%) 
 
1.00 (– –) 
1.88 (0.96, 3.68) 
.068 
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Table 2: Predictors of prophylactic anticonvulsant initiation 
 
Model OR (95% CI) p-value 
Age 0.97 (0.95, 0.99) <.001 
Craniotomy 
Yes 
No 
 
3.06 (1.51, 6.20) 
1.00 (– –) 
.002 
Initial NIHSS 
≤ 7 (median) 
            >7 
 
1.00 (– –) 
2.31 (1.40, 3.79) 
.001 
Lobar 
Yes 
No 
 
2.94 (1.76, 4.91) 
1.00 (– –) 
<.001 
Prior ICH 
Yes 
No 
 
2.36 (1.10, 5.07) 
1.00 (– –) 
.028 
 
  
  MACKEY 19 
 
Table 3: Propensity-matched anticonvulsant prophylaxis vs. no prophylaxis 
 
 Prophylactic 
anticonvulsants 
N=93 
No prophylaxis 
N=93 
p-value 
Age, mean (SD)  62.3 ± 13.5   62.0 ± 14.4  .908 
Female  47 (50.5%) 50 (53.8%) .660 
Black 32 (34.4%) 28 (30.1%) .530 
Baseline mRS, median 
(IQR) 1 (0, 1) 1 (0, 1) .842 
GCS, median (IQR) 13 (9, 15) 14 (9, 15) .729 
Initial NIHSS, median 
(IQR) 12 (4, 19) 9 (3, 26) .634 
ICH volume (mL), median 
(IQR) 21.9 (7.5, 39.4) 17.5 (5.0, 44.7) .778 
Subarachnoid extension  13 (14.0%) 15 (16.1%) .682 
Intraventricular extension 50 (53.8%) 54 (58.1%) .555 
Supratentorial 87 (93.5%) 83 (89.2%) .296 
Lobar 46 (49.5%) 45 (48.4%) .883 
Initial SBP, mmHg (SD)  187.7 ± 37.5   185.8 ± 42.8  .748 
Initial DBP, mmHg (SD)  104.2 ± 27.0   103.3 ± 28.2  .833 
Charlson, median (IQR) 1 (0, 2) 1 (0, 2) .985 
Craniotomy  15 (16.1%) 16 (17.2%) .844 
Prior ICH  11 (11.8%) 15 (16.1%) .398 
Prior ischemic stroke  11 (11.8%) 14 (15.1%) .519 
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Table 4: Univariate logistic regression for poor functional outcomes (mRS 4-6) using 
propensity-matched cohort (N=186) 
 
 mRS 0-3 
(N = 53) 
mRS 4-6 
(N = 133) 
Unadjusted OR (95% 
CI) for predicting  
mRS 4-6 
p-value 
N (%) N (%) 
Age 
Q1 (22-53) 
Q2 (54-62) 
Q3 (63-71) 
Q4 (72-95) 
 
19 (38.8%) 
16 (30.8%) 
11 (28.2%) 
7 (15.2%) 
 
30 (61.2%) 
36 (69.2%) 
28 (71.8%) 
39 (84.8%) 
 
1.00 (– –) 
1.43 (0.63, 3.25) 
1.61 (0.65, 3.98) 
3.53 (1.31, 9.48) 
.097 
Sex 
Female 
Male 
 
26 (26.8%) 
27 (30.3%) 
 
71 (73.2%) 
62 (69.7%) 
 
1.19 (0.63, 2.25) 
1.00 (– –) 
.594 
Race 
Black 
Non-Black 
 
14 (23.3%) 
39 (31.0%) 
 
46 (76.7%) 
87 (69.0%) 
 
1.47 (0.73, 2.99) 
1.00 (– –) 
.284 
Baseline mRS 
0-1 
2-3 
 
47 (32.2%) 
6 (15.0%) 
 
99 (67.8%) 
34 (85.0%) 
 
1.00 (– –) 
2.69 (1.06, 6.85) 
.038 
GCS, median (IQR)  - 0.65 (0.54, 0.79) <.001 
Initial NIHSS 
≤ 11 (median) 
        > 11                                                 
 
48 (49.5%) 
5 (5.6%)
 
49 (50.5%) 
84 (94.4%) 
 
1.00 (– –) 
16.46 (6.14, 44.11) 
<.001 
ICH volume (mL) 
Q1 (0-6.0) 
Q2 (6.1-18.6) 
Q3 (18.7-43.3) 
Q4 (43.4-130.6) 
 
23 (46.9%) 
16 (36.4%) 
12 (25.5%) 
2 (4.3%) 
 
26 (53.1%) 
28 (63.6%) 
35 (74.5%) 
44 (95.7%) 
 
1.00 (– –) 
1.55 (0.67, 3.56) 
2.58 (1.09, 6.12) 
19.46 (4.24, 89.35) 
<.001 
Subarachnoid extension  
Yes 
No 
 
2 (7.1%) 
51 (32.3%) 
 
26 (92.9%) 
107 (67.7%) 
 
6.20 (1.42, 27.12) 
1.00 (– –) 
.016 
Intraventricular extension 
Yes 
No 
 
17 (16.3%) 
36 (43.9%) 
 
87 (83.7%) 
46 (56.1%) 
 
4.01 (2.03, 7.89) 
1.00 (– –) 
<.001 
Supratentorial  
Yes 
No 
 
48 (28.2%) 
5 (31.2%) 
 
122 (71.8%) 
11 (68.8%) 
 
1.15 (0.38, 3.50) 
1.00 (– –) 
.799 
Lobar  
Yes 
No 
 
30 (33.0%) 
23 (24.2%) 
 
61 (67.0%) 
72 (75.8%) 
 
1.00 (– –) 
1.54 (0.81, 2.92) 
.187 
Initial SBP, mmHg 
Q1 (107-156) 
Q2 (157-182.5) 
Q3 (182.6-211) 
Q4 (212-282) 
 
15 (31.2%) 
17 (33.3%) 
9 (21.4%) 
12 (26.7%) 
 
33 (68.8%) 
34 (66.7%) 
33 (78.6%) 
33 (73.3%) 
 
1.00 (– –) 
0.91 (0.39, 2.11) 
1.67 (0.64, 4.34) 
1.25 (0.51, 3.07) 
.605 
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 mRS 0-3 
(N = 53) 
mRS 4-6 
(N = 133) 
Unadjusted OR (95% 
CI) for predicting  
mRS 4-6 
p-value 
N (%) N (%) 
Initial DBP, mmHg 
Q1 (47-86) 
Q2 (87-100) 
Q3 (101-112) 
Q4 (113-183) 
 
12 (25.5%) 
18 (34.6%) 
12 (29.3%) 
11 (23.9%) 
 
35 (74.5%) 
34 (65.4%) 
29 (70.7%) 
35 (76.1%) 
 
1.00 (– –) 
0.65 (0.27, 1.55) 
0.83 (0.32, 2.12) 
1.09 (0.43, 2.80) 
.652 
Charlson 
0-1 
>1 
 
37 (29.8%) 
16 (25.8%) 
 
87 (70.2%) 
46 (74.2%) 
 
1.00 (– –) 
1.22 (0.62, 2.43) 
.566 
Craniotomy  
Yes 
No 
 
8 (25.8%) 
45 (29.0%) 
 
23 (74.2%) 
110 (71.0%) 
 
1.18 (0.49, 2.82) 
1.00 (– –) 
.717 
Prior ICH 
Yes 
No 
 
8 (33.8%) 
45 (28.1%) 
 
18 (69.2%) 
115 (71.9%) 
 
1.00 (– –) 
1.14 (0.46, 2.80) 
.782 
Prior ischemic stroke 
Yes 
No 
 
4 (16.0%) 
49 (30.4%) 
 
21 (84.0%) 
112 (69.6%) 
 
2.30 (0.75, 7.04) 
1.00 (– –) 
.146 
Prophylactic anticonvulsant  
Yes 
No 
 
24 (25.8%) 
29 (31.2%) 
 
69 (74.2%) 
64 (68.8%) 
 
1.30 (0.69, 2.47) 
1.00 (– –) 
.417 
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Table 5: Predictors of poor outcome (mRS 4-6) at hospital discharge 
 
Model OR (95% CI) p-value 
Prophylactic anticonvulsant 
Yes 
No 
 
1.41 (0.61, 3.29) 
1.00 (– –) 
.424 
Initial NIHSS 
≤ 11 (median) 
           >11 
 
1.00 (– –) 
13.95 (4.80, 40.50) 
<.001 
ICH volume (mL) 
Q1 (0-6.0) 
Q2 (6.1-18.6) 
Q3 (18.7-43.3) 
Q4 (43.4-130.6) 
 
1.00 (– –) 
2.02 (0.72, 5.66) 
2.24 (0.73, 6.84) 
19.28 (3.58, 103.71) 
.007 
Intraventricular extension 
Yes 
No 
 
3.33 (1.41, 7.88) 
1.00 (– –) 
.006 
Baseline mRS 
0-1 
2-3 
 
1.00 (– –) 
5.05 (1.53, 16.66) 
.008 
 
 
 
 
 
